{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:54:07Z","timestamp":1781718847409,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1136\/ijgc-2018-000071","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T13:29:26Z","timestamp":1547126966000},"page":"430-433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Trials in progress: IMagyn050\/GOG 3015\/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer"],"prefix":"10.1016","volume":"29","clinical-trial-number":[{"clinical-trial-number":"nct03038100","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00262847","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03038100","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02655016","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02477644","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02718417","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kathleen N","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2018-000071_bb0010","author":"American Cancer Society","year":"2018"},{"key":"10.1136\/ijgc-2018-000071_bb0015","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/AOG.0000000000000981","article-title":"Characteristics of long-term survivors of epithelial ovarian cancer","volume":"126","author":"Cress","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2018-000071_bb0020","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2018-000071_bb0025","author":"AccessData","year":"2017","journal-title":"FDA label of Avelumab"},{"issue":"15_suppl","key":"10.1136\/ijgc-2018-000071_bb0030","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.5517","article-title":"Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: a NRG Oncology\/Gynecologic Oncology Group (GOG) study","volume":"36","author":"Burger","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/ijgc-2018-000071_bb0035","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2018-000071_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1136\/ijgc-2018-000071_bb0045","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1136\/ijgc-2018-000071_bb0050","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2018-000071_bb0055","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1136\/ijgc-2018-000071_bb0060","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1136\/ijgc-2018-000071_bb0065","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2018-000071_bb0070","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1136\/ijgc-2018-000071_bb0075","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","article-title":"PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction","volume":"19","author":"Abiko","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2018-000071_bb0080","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2018-000071_bb0085","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/sj.bjc.6602476","article-title":"The role of dendritic cell precursors in tumour vasculogenesis","volume":"92","author":"Coukos","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2018-000071_bb0090","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/bjc.2012.468","article-title":"VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2","volume":"107","author":"Gavalas","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2018-000071_bb0095","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.4049\/jimmunol.178.3.1505","article-title":"Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy","volume":"178","author":"Bouzin","year":"2007","journal-title":"J Immunol"},{"key":"10.1136\/ijgc-2018-000071_bb0100","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","article-title":"Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer","volume":"70","author":"Shrimali","year":"2010","journal-title":"Cancer Res"},{"issue":"15_suppl","key":"10.1136\/ijgc-2018-000071_bb0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4505","article-title":"IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun)","volume":"35","author":"Atkins","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/ijgc-2018-000071_bb0110","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24010892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24010892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2018-000071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:24:39Z","timestamp":1753233879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24010892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1048891X24010892"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2018-000071","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trials in progress: IMagyn050\/GOG 3015\/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2018-000071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}